These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

377 related items for PubMed ID: 17472719

  • 1. Peptide-beta2-microglobulin-major histocompatibility complex expressing cells are potent antigen-presenting cells that can generate specific T cells.
    Obermann S, Petrykowska S, Manns MP, Korangy F, Greten TF.
    Immunology; 2007 Sep; 122(1):90-7. PubMed ID: 17472719
    [Abstract] [Full Text] [Related]

  • 2. Long-lived antitumor CD8+ lymphocytes for adoptive therapy generated using an artificial antigen-presenting cell.
    Butler MO, Lee JS, Ansén S, Neuberg D, Hodi FS, Murray AP, Drury L, Berezovskaya A, Mulligan RC, Nadler LM, Hirano N.
    Clin Cancer Res; 2007 Mar 15; 13(6):1857-67. PubMed ID: 17363542
    [Abstract] [Full Text] [Related]

  • 3. An antigen-targeted approach to adoptive transfer therapy of cancer.
    Valmori D, Pittet MJ, Rimoldi D, Liénard D, Dunbar R, Cerundolo V, Lejeune F, Cerottini JC, Romero P.
    Cancer Res; 1999 May 01; 59(9):2167-73. PubMed ID: 10232604
    [Abstract] [Full Text] [Related]

  • 4. Artificial antigen-presenting cells transduced with telomerase efficiently expand epitope-specific, human leukocyte antigen-restricted cytotoxic T cells.
    Dupont J, Latouche JB, Ma C, Sadelain M.
    Cancer Res; 2005 Jun 15; 65(12):5417-27. PubMed ID: 15958591
    [Abstract] [Full Text] [Related]

  • 5. A parathyroid-hormone-related-protein (PTH-rP)-specific cytotoxic T cell response induced by in vitro stimulation of tumour-infiltrating lymphocytes derived from prostate cancer metastases, with epitope peptide-loaded autologous dendritic cells and low-dose IL-2.
    Correale P, Micheli L, Vecchio MT, Sabatino M, Petrioli R, Pozzessere D, Marsili S, Giorgi G, Lozzi L, Neri P, Francini G.
    Br J Cancer; 2001 Nov 30; 85(11):1722-30. PubMed ID: 11742494
    [Abstract] [Full Text] [Related]

  • 6. Comparison of various sources of antigen-presenting cells for the generation of GP2-tumor peptide specific cytotoxic T-lymphocytes.
    Peiper M, Goedegebuure PS, Alldinger I, Knoefel WT, Izbicki JR, Eberlein TJ.
    Anticancer Res; 2002 Nov 30; 22(6A):3357-63. PubMed ID: 12530087
    [Abstract] [Full Text] [Related]

  • 7. HLA-Ig-based artificial antigen-presenting cells: setting the terms of engagement.
    Oelke M, Schneck JP.
    Clin Immunol; 2004 Mar 30; 110(3):243-51. PubMed ID: 15047202
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Preparation of fully activated dendritic cells capable of priming tumor-specific cytotoxic T lymphocytes in patients with metastatic cancer using penicillin-killed streptococcus pyogenes (OK432) and anti-CD40 antibody.
    Kontani K, Teramoto K, Ozaki Y, Sawai S, Tezuka N, Ishida H, Kajino K, Fujino S, Yamauchi A, Taguchi O, Kannagi R, Yokomise H, Ogasawara K.
    Oncol Rep; 2007 Apr 30; 17(4):895-902. PubMed ID: 17342333
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. In vitro expansion of polyclonal T-cell subsets for adoptive immunotherapy by recombinant modified vaccinia Ankara.
    La Rosa C, Wang Z, Lacey SF, Lalimarmo MM, Krishnan A, Longmate J, Diamond DJ.
    Exp Hematol; 2006 Apr 30; 34(4):497-507. PubMed ID: 16569596
    [Abstract] [Full Text] [Related]

  • 12. Direct detection and quantitation of a distinct T-cell epitope derived from tumor-specific epithelial cell-associated mucin using human recombinant antibodies endowed with the antigen-specific, major histocompatibility complex-restricted specificity of T cells.
    Cohen CJ, Hoffmann N, Farago M, Hoogenboom HR, Eisenbach L, Reiter Y.
    Cancer Res; 2002 Oct 15; 62(20):5835-44. PubMed ID: 12384546
    [Abstract] [Full Text] [Related]

  • 13. CD40-stimulated B lymphocytes pulsed with tumor antigens are effective antigen-presenting cells that can generate specific T cells.
    Lapointe R, Bellemare-Pelletier A, Housseau F, Thibodeau J, Hwu P.
    Cancer Res; 2003 Jun 01; 63(11):2836-43. PubMed ID: 12782589
    [Abstract] [Full Text] [Related]

  • 14. Induction of human cytotoxic T lymphocytes by artificial antigen-presenting cells.
    Latouche JB, Sadelain M.
    Nat Biotechnol; 2000 Apr 01; 18(4):405-9. PubMed ID: 10748520
    [Abstract] [Full Text] [Related]

  • 15. Isolation and characterization of human recombinant antibodies endowed with the antigen-specific, major histocompatibility complex-restricted specificity of T cells directed toward the widely expressed tumor T-cell epitopes of the telomerase catalytic subunit.
    Lev A, Denkberg G, Cohen CJ, Tzukerman M, Skorecki KL, Chames P, Hoogenboom HR, Reiter Y.
    Cancer Res; 2002 Jun 01; 62(11):3184-94. PubMed ID: 12036932
    [Abstract] [Full Text] [Related]

  • 16. Tumor antigen-specific T-cell expansion is greatly facilitated by in vivo priming.
    Dang Y, Knutson KL, Goodell V, dela Rosa C, Salazar LG, Higgins D, Childs J, Disis ML.
    Clin Cancer Res; 2007 Mar 15; 13(6):1883-91. PubMed ID: 17363545
    [Abstract] [Full Text] [Related]

  • 17. Efficient presentation of naturally processed HLA class I peptides by artificial antigen-presenting cells for the generation of effective antitumor responses.
    Hirano N, Butler MO, Xia Z, Berezovskaya A, Murray AP, Ansén S, Nadler LM.
    Clin Cancer Res; 2006 May 15; 12(10):2967-75. PubMed ID: 16707591
    [Abstract] [Full Text] [Related]

  • 18. A novel system of artificial antigen-presenting cells efficiently stimulates Flu peptide-specific cytotoxic T cells in vitro.
    Han H, Peng JR, Chen PC, Gong L, Qiao SS, Wang WZ, Cui ZQ, Yu X, Wei YH, Leng XS.
    Biochem Biophys Res Commun; 2011 Aug 05; 411(3):530-5. PubMed ID: 21756876
    [Abstract] [Full Text] [Related]

  • 19. The effect of artificial antigen-presenting cells with preclustered anti-CD28/-CD3/-LFA-1 monoclonal antibodies on the induction of ex vivo expansion of functional human antitumor T cells.
    Zappasodi R, Di Nicola M, Carlo-Stella C, Mortarini R, Molla A, Vegetti C, Albani S, Anichini A, Gianni AM.
    Haematologica; 2008 Oct 05; 93(10):1523-34. PubMed ID: 18728033
    [Abstract] [Full Text] [Related]

  • 20. Purification of melanoma reactive T cell by using a monocyte-based solid phase T-cell selection system for adoptive therapy.
    Li J, Mookerjee B, Wagner J.
    J Immunother; 2008 Jan 05; 31(1):81-8. PubMed ID: 18157015
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.